Urovant Sciences (NASDAQ:UROV) announced its earnings results on Thursday. The company reported ($0.96) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.96), Fidelity Earnings reports.

Shares of Urovant Sciences stock traded up $0.24 during trading hours on Friday, reaching $7.79. 12,452 shares of the company were exchanged, compared to its average volume of 60,245. Urovant Sciences has a 1 year low of $4.05 and a 1 year high of $14.49.

In related news, major shareholder Qvt Associates Gp Llc acquired 21,338 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were acquired at an average price of $8.31 per share, with a total value of $177,318.78. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Patrick Machado acquired 21,608 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were bought at an average cost of $7.54 per share, for a total transaction of $162,924.32. The disclosure for this purchase can be found here. Insiders have bought 127,737 shares of company stock worth $1,001,153 in the last ninety days.

A number of analysts have issued reports on the company. Zacks Investment Research raised Urovant Sciences from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Thursday, April 18th. HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Urovant Sciences in a research report on Friday, March 22nd. Finally, SunTrust Banks assumed coverage on Urovant Sciences in a research report on Friday, March 15th. They set a “buy” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.13.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/urovant-sciences-nasdaqurov-issues-earnings-results/3041484.html.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

See Also: Outstanding Shares

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.